Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal dexmedetomidine dose comparison for preoperative calmness and agitation in young children undergoing cochlear implantation
IRCT20250505065605N1Phase 4Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of dexmedetomidine in separation anxiety disorder (SAD) and sensorineural hearing loss (SNHL) (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Calmness score and Agitation score. Started May 2025; status: completed.
02
Drugs
dexmedetomidine
03
Conditions
separation anxiety disorder (SAD)sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on IRCT20250505065605N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20250505065605N1.